Cover Image
市場調查報告書

Verva Pharmaceuticals Limited - 產品平台分析

Verva Pharmaceuticals Limited - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 259372
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Verva Pharmaceuticals Limited - 產品平台分析 Verva Pharmaceuticals Limited - Product Pipeline Review - 2014
出版日期: 2014年07月31日 內容資訊: 英文 24 Pages
簡介

Verva Pharmaceuticals Limited 是開發第二型糖尿病,及非酒精性脂肪肝病(NAFLD/NASH) 、相關併發症的治療藥的製藥公司,正在發現生物學性標的,並賦與特微計劃。該公司致力於預防及消除肥胖及其併發症,同時也進行發現新一代分子這個治療標的計劃,具有防止新肥胖細胞形成的技術。

本報告提供Verva Pharmaceuticals Limited 的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Verva Pharmaceuticals Limited 基本資料

Verva Pharmaceuticals Limited 概要

  • 主要資訊
  • 企業資料

Verva Pharmaceuticals Limited :R&D概要

  • 主要的治療範圍

Verva Pharmaceuticals Limited :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Verva Pharmaceuticals Limited :開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Verva Pharmaceuticals Limited :藥物簡介

  • methazolamide
  • Small Molecule to Inhibit Inosine Monophosphate Dehydrogenase for Obesity
  • VVP-100-X

Verva Pharmaceuticals Limited :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Verva Pharmaceuticals Limited :最近的開發平台趨勢

Verva Pharmaceuticals Limited :暫停中的計劃

Verva Pharmaceuticals Limited :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC05798CDB

Summary

Global Markets Direct's, 'Verva Pharmaceuticals Limited - Product Pipeline Review - 2014', provides an overview of the Verva Pharmaceuticals Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Verva Pharmaceuticals Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Verva Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Verva Pharmaceuticals Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Verva Pharmaceuticals Limited's pipeline products

Reasons to buy

  • Evaluate Verva Pharmaceuticals Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Verva Pharmaceuticals Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Verva Pharmaceuticals Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Verva Pharmaceuticals Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Verva Pharmaceuticals Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Verva Pharmaceuticals Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Verva Pharmaceuticals Limited Snapshot
    • Verva Pharmaceuticals Limited Overview
    • Key Information
    • Key Facts
  • Verva Pharmaceuticals Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Verva Pharmaceuticals Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Verva Pharmaceuticals Limited - Pipeline Products Glance
    • Verva Pharmaceuticals Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Verva Pharmaceuticals Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Verva Pharmaceuticals Limited - Drug Profiles
    • methazolamide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Inosine Monophosphate Dehydrogenase for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VVP-100-X
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Verva Pharmaceuticals Limited - Pipeline Analysis
    • Verva Pharmaceuticals Limited - Pipeline Products by Target
    • Verva Pharmaceuticals Limited - Pipeline Products by Route of Administration
    • Verva Pharmaceuticals Limited - Pipeline Products by Molecule Type
    • Verva Pharmaceuticals Limited - Pipeline Products by Mechanism of Action
  • Verva Pharmaceuticals Limited - Recent Pipeline Updates
  • Verva Pharmaceuticals Limited - Dormant Projects
  • Verva Pharmaceuticals Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Verva Pharmaceuticals Limited, Key Information
  • Verva Pharmaceuticals Limited, Key Facts
  • Verva Pharmaceuticals Limited - Pipeline by Indication, 2014
  • Verva Pharmaceuticals Limited - Pipeline by Stage of Development, 2014
  • Verva Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2014
  • Verva Pharmaceuticals Limited - Out-Licensed Products in Pipeline, 2014
  • Verva Pharmaceuticals Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Verva Pharmaceuticals Limited - Phase II, 2014
  • Verva Pharmaceuticals Limited - Preclinical, 2014
  • Verva Pharmaceuticals Limited - Pipeline by Target, 2014
  • Verva Pharmaceuticals Limited - Pipeline by Route of Administration, 2014
  • Verva Pharmaceuticals Limited - Pipeline by Molecule Type, 2014
  • Verva Pharmaceuticals Limited - Pipeline Products by Mechanism of Action, 2014
  • Verva Pharmaceuticals Limited - Recent Pipeline Updates, 2014
  • Verva Pharmaceuticals Limited - Dormant Developmental Projects,2014

List of Figures

  • Verva Pharmaceuticals Limited - Pipeline by Top 10 Indication, 2014
  • Verva Pharmaceuticals Limited - Pipeline by Stage of Development, 2014
  • Verva Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2014
  • Verva Pharmaceuticals Limited - Pipeline by Top 10 Route of Administration, 2014
  • Verva Pharmaceuticals Limited - Pipeline by Top 10 Molecule Type, 2014
Back to Top